NCT00895804

Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: University Hospital, Basel, Switzerland · Academic / Other
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

MDMA (3,4-Methylenedioxymethamphetamine, "Ecstasy") produces tachycardia, hypertension, hyperthermia, and other acute adverse effects. Ecstasy use has also been associated with rare cardio- and cerebrovascular complications. The role of beta-blockers in the treatment of cardiovascular and adverse effects of MDMA is unknown.

Detailed description

We investigated the interactive effects of the beta-blocker pindolol (20 mg) with MDMA (1.6 mg/kg) on heart rate, blood pressure, body temperature, and adverse effects in a double-blind placebo-controlled study in 16 healthy subjects.

Conditions

• Mood Disorder
• Substance-Related Disorders
• Amphetamine-Related Disorders

Interventions

Type	Name	Description
DRUG	MDMA	capsule, 1.6 mg/kg body weight, single dose
DRUG	Pindolol	capsule of 20mg pindolol, single dose 1h before MDMA

Timeline

• Start date: 2001-06-01
• Primary completion: 2002-03-01
• Completion: 2002-03-01
• First posted: 2009-05-08
• Last updated: 2009-06-15

Locations

1 site across 1 country: Switzerland